Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.54 USD
0.00 (0.00%)
Updated Sep 13, 2024 04:00 PM ET
3-Hold of 5 3
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[ALIM]
Reports for Purchase
Showing records 1 - 20 ( 98 total )
Industry: Medical - Biomedical and Genetics
ANI Pharmaceuticals Acquires Alimera Sciences; Downgrading to Neutral with $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Buy; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
U.K. NICE Final Guidance Recommends Access to ILUVIEN; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
NEW DAY Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
YUTIQ Acquired for $82.5M Cash Plus Royalties; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Marketing Authorization Application for ILUVIEN Submitted in Switzerland; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Solid Product Sales Growth in 2Q22; Reiterate Buy; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
1Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
2021 Financial Results Reported; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Two-Year Real-World Data Show Reduction in Treatment Burden; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
2Q21 Financial Results Reported; Reiterate Buy; Reducing PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Industry: Medical - Biomedical and Genetics
1Q21 Financial Results; Top Line In Line, Bottom Line Miss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y